Dr. Stanley J. Szefler is the Helen Wohlberg and Herman Lambert Chair in Pharmacokinetics, Head of Pediatric Clinical Pharmacology, Director of the Pediatrics Section of the Weinberg Clinical Research Unit at National Jewish Health in Denver, Colorado. He also is Professor of Pediatrics and Pharmacology at the University of Colorado at Denver Health Sciences Center. Dr. Szefler’s major goals are to contribute to continuing developments in the management of childhood asthma, especially in the areas of individualizing asthma treatment.

He is the Principal Investigator for the Denver sites of the National Heart, Lung, and Blood Institute’s (NHLBI) Childhood Asthma Management Program and the Childhood Asthma Research and Education (CARE) Network.  He is Co-Principal Investigator for the National Institute of Allergy and Infectious Diseases’ Inner-City Asthma Consortium (ICAC) and Co-Investigator for the NHLBI’s Asthma Clinical Research Network (ACRN).  In addition, he is the Director of a Colorado Cancer, Cardiovascular and Pulmonary Disease Grant to improve asthma control in the Denver Public School System.

Dr. Szefler is a member of the Expert Panel-3 for the NHLBI’s National Asthma Education and Prevention Program on “Guidelines for the Diagnosis and Management of Asthma” and the Colorado Asthma Guidelines Panel.  In addition, Dr. Szefler is the Deputy Editor for the Journal of Allergy and Clinical Immunology. He has published more than 350 scientific articles, scholarly reviews, and book chapters. Dr. Szefler received pharmacy and medical degrees from the State University of New York at Buffalo. He then received residency training in pediatrics, followed by fellowship training in clinical pharmacology and allergy-immunology at the Children’s Hospital of Buffalo and State University of New York at Buffalo.

Moderator

Lev is an Academic in Residence and Senior Writer at BioCentury,
covering advanced topics in discovery-stage and preclinical biomedical
science.  He holds a Ph.D. in biochemistry from the University of
California, San Francisco. Lev joins the team during a sabbatical from a
Burroughs Wellcome Fund fellowship at UCSF.

Urban Land Institute of Colorado is holding a walking tour and panelist discussion at Fitzsimons to discuss the history of the former Army Medical Center.

The tour will include:

• Ben Nighthorse Campbell Center
• Bioscience Park Center incubator (tour will be led by Vicki Jenings, Director of Business Relations for Fitzsimons Redevelopment Authority)
• Historic Building 500. This Art Deco gem was built in 1941 and includes a “Western White House” at the Eisenhower Suite, where the - President convalesced for two months after a 1954 heart attack.
• University of Colorado Hospital Anschutz Cancer Pavilion & Other University of Colorado Buildings
• Barbara Davis Center for Childhood Diabetes. This will focus on BDC’s effort to treat and cure Type 1 diabetes.
• 21 Fitzsimons A mixed-use project developed by the Pauls Corporation, 21 Fitz is also our last stop for a happy hour. Melding both contemporary and classic design elements that complement the Anschutz Medical Campus, 21 Fitzsimons features luxury apartment homes plus 16,000 square feet of ground floor retail space.

For more information please contact ULI Colorado: 303.893.1760 or email Colorado@uli.org

Beacon Biotechnology, one of our tenants at the BioScience Park Center in the Fitzsimons Life Science District, created a new disposable medical device, the BrightSpot, that allows clinicians to see faster disease results, from just a drop of fluid, than currently available technologies. Read the full article.

We’ll be playing at the 2009 Bioscience Bogey on June 22th. Will you?